Cannabinoid Emulsion Compositions for Treating Ophthalmic Conditions
Summary
Rhodes Technologies published patent application US20260090988A1 for stable cannabinoid emulsion compositions designed for ocular delivery to treat ophthalmic conditions including glaucoma. The application, filed July 29, 2025, and published April 2, 2026, names inventors Ping Chang, Zhenze Hu, and Yuanyuan Tao. This publication represents a patent application only and does not grant enforceable patent rights.
What changed
Rhodes Technologies filed and published a patent application for emulsion compositions containing cannabinoid compounds for treating ophthalmic conditions, specifically glaucoma. The compositions are described as stable, well-tolerated, and capable of delivering therapeutically effective amounts of cannabinoids to target sites within or on the surface of the eye. The application covers methods of making and using these compositions for ocular neuroprotection.
This is a patent application publication only and does not create any compliance obligations or regulatory requirements. No regulatory action is required from pharmaceutical manufacturers or other parties. Competitors developing similar ophthalmic cannabinoid formulations should monitor this application for potential future patent claims once granted.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS
Application US20260090988A1 Kind: A1 Apr 02, 2026
Assignee
Rhodes Technologies
Inventors
Ping CHANG, Zhenze HU, Yuanyuan TAO
Abstract
The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabinoids to target sites, including sites on the surface of and/or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and/or to treat ophthalmic conditions such as glaucoma.
CPC Classifications
A61K 9/1075 A61K 9/0014 A61K 9/0019 A61K 9/0048 A61K 9/06 A61K 31/352 A61K 31/658 A61K 47/02 A61K 47/10 A61K 47/44 A61P 27/04 A61P 29/00
Filing Date
2025-07-29
Application No.
19283647
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.